Skip to Main Content

Author Details

Nabeel Bardeesy
Massachusetts General Hospital
1992
224
95
Nevan J Krogan (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37843855Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma.Clin Cancer Res2024
36309131Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment.J Hepatol2023
37961514DrugMap: A quantitative pan-cancer analysis of cysteine ligandability.bioRxiv2023
37794185The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity.Nature2023
37695631KRAS Wild-Type Pancreatic Cancer: Decoding Genomics, Unlocking Therapeutic Potential.Clin Cancer Res2023
37942963Targeting ribosome biogenesis reinforces ERK-dependent senescence in pancreatic cancer.Cell Cycle2023
37192619Systematic identification of anticancer drug targets reveals a nucleus-to-mitochondria ROS-sensing pathway.Cell2023
36958689Histone Deacetylase 6 Inhibition Exploits Selective Metabolic Vulnerabilities in LKB1 Mutant, KRAS Driven NSCLC.J Thorac Oncol2023
37019082NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer.Cell Metab2023
36945474Identification of chemotherapy targets reveals a nucleus-to-mitochondria ROS sensing pathway.bioRxiv2023
37131623<i>In vivo</i> metabolomics identifies CD38 as an emergent vulnerability in <i>LKB1</i> -mutant lung cancer.bioRxiv2023
36697706Immunology and immunotherapy of cholangiocarcinoma.Nat Rev Gastroenterol Hepatol2023
36747853Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy.bioRxiv2023
36692000Oncogenic PKA signaling increases c-MYC protein expression through multiple targetable mechanisms.Elife2023
36914816SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers.Nat Cancer2023
36841242NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer.Cell Metab2023
33431577Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma.Gut2022
35508175ISL2 is a putative tumor suppressor whose epigenetic silencing reprograms the metabolism of pancreatic cancer.Dev Cell2022
35646902Nuclear GSK-3β and Oncogenic KRas Lead to the Retention of Pancreatic Ductal Progenitor Cells Phenotypically Similar to Those Seen in IPMN.Front Cell Dev Biol2022
35420673EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma.Cancer Discov2022
35565279Oncogenic Kras-Mediated Cytokine CCL15 Regulates Pancreatic Cancer Cell Migration and Invasion through ROS.Cancers (Basel)2022
35482409Multiomic analysis of microRNA-mediated regulation reveals a proliferative axis involving miR-10b in fibrolamellar carcinoma.JCI Insight2022
36056177Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma.NPJ Precis Oncol2022
36089135The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.Ann Oncol2022
35226770Biology of IDH mutant cholangiocarcinoma.Hepatology2022
34848557Mutant IDH Inhibits IFNγ-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma.Cancer Discov2022
34142094ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer.Nat Cancer2021
33709779Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-<i>IDH1</i> cholangiocarcinoma.Future Oncol2021
33926920<i>FGFR2</i> Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma.Cancer Discov2021
33689705A gene expression signature associated with ''K-Ras addiction'' reveals regulators of EMT and tumor cell survival.Cancer Cell2021
33915015Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2.Angew Chem Int Ed Engl2021
34381046Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulation.Nat Commun2021
34535664A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery.Nat Commun2021
33958764Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer.Nat Nanotechnol2021
31378984Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.Hepatology2020
32081369Corrigendum to High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype12 [Translational Oncology Volume 12, Issue 2, February 2019, Pages 256-268].Transl Oncol2020
32835448Remembering Dr. Supriya "Shoop" Saha.Oncologist2020
32611647Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI.Clin Cancer Res2020
32273287REDD1 loss reprograms lipid metabolism to drive progression of <i>RAS</i> mutant tumors.Genes Dev2020
30439626High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype.Transl Oncol2019
31695192Author Correction: LKB1 loss links serine metabolism to DNA methylation and tumorigenesis.Nature2019
31386860EGFR Pathway Links Amino Acid Levels and Induction of Macropinocytosis.Dev Cell2019
31328154LKB1 specifies neural crest cell fates through pyruvate-alanine cycling.Sci Adv2019
30951568Road map for fibrolamellar carcinoma: progress and goals of a diversified approach.J Hepatocell Carcinoma2019
30836093HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.Gastroenterology2019
30978357Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of Hepatitis C Virus-Infected Cells and Liver to Identify Pathways Associated With Disease Development.Gastroenterology2019
31109923TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.Cancer Discov2019
30936192Corrigendum: Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome.Genes Dev2019
31134896Transcriptional control of subtype switching ensures adaptation and growth of pancreatic cancer.Elife2019
30683911Quasimesenchymal phenotype predicts systemic metastasis in pancreatic ductal adenocarcinoma.Mod Pathol2019
  • 1 - 50 of 224

Recommended Authors

Huwate Yeerna
Moores Cancer Center, University of California
Career Start Year 2015
Number of shared co-authors 3
Shruthy Suresh
Memorial Sloan Kettering Cancer Center
Career Start Year 2013
Number of shared co-authors 1
Tuo Zhang
Weill Cornell Medical College.
Career Start Year 2013
Number of shared co-authors 0
Yibu Chen
USC Libraries Bioinformatic Services of the University of Southern California
Career Start Year 2012
Number of shared co-authors 0
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 2
Faiyaz Notta
2Ontario Institute for Cancer Research
Career Start Year 2009
Number of shared co-authors 4
Helen He Zhu
Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine
Career Start Year 2009
Number of shared co-authors 0
Amanda R Wasylishen
The University of Texas MD Anderson Cancer Center
Career Start Year 2008
Number of shared co-authors 3
Christopher A Bristow
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 27
Daniel Schramek
University of Toronto
Career Start Year 2005
Number of shared co-authors 2
Kurt W Fisher
University of Nebraska Medical Center
Career Start Year 2004
Number of shared co-authors 0
Kristopher K Frese
Cancer Research UK Manchester Institute, University of Manchester
Career Start Year 2003
Number of shared co-authors 3
Monte M Winslow
Stanford University School of Medicine
Career Start Year 2002
Number of shared co-authors 8
Susan L Woods
Adelaide Medical School, University of Adelaide
Career Start Year 2002
Number of shared co-authors 2
Andrea Viale
The University of Texas MD Anderson Cancer Center
Career Start Year 2001
Number of shared co-authors 10
Eric A Collisson
University of California san francisco
Career Start Year 1999
Number of shared co-authors 20
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 1
Jianjun Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 1998
Number of shared co-authors 8
Alexander D Borowsky
University of California Davis Health
Career Start Year 1995
Number of shared co-authors 3
Andrei Goga
University of California San Francisco
Career Start Year 1993
Number of shared co-authors 9
Tatsuhiro Shibata
Kurume University School of Medicine
Career Start Year 1993
Number of shared co-authors 8
Suzanne Carreira
The Institute of Cancer Research
Career Start Year 1990
Number of shared co-authors 3
E Alejandro Sweet-Cordero
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 8
Nathan Bahary
University of Pittsburgh
Career Start Year 1989
Number of shared co-authors 2
Eldad Zacksenhaus
University of Toronto
Career Start Year 1988
Number of shared co-authors 4
Daniel S Peeper
Netherlands Cancer Institute
Career Start Year 1987
Number of shared co-authors 4
Francisco X Real
Spanish National Cancer Research Centre-CNIO
Career Start Year 1983
Number of shared co-authors 3
David J Adams
Wellcome Sanger Institute
Career Start Year 1980
Number of shared co-authors 14
Francisca Vazquez
Broad Institute of MIT and Harvard
Career Start Year 1979
Number of shared co-authors 24
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 52

Collaborators

Norman E Sharpless
National Cancer Institute
Co-authored papers 15
Krushna C Patra
Harvard Medical School
Co-authored papers 9
Lynda Chin
Co-authored papers 9
Cyril H Benes
Co-authored papers 8
Rakesh K Jain
Massachusetts General Hospital, Harvard Medical School
Co-authored papers 8
David Neil Hayes
Center for Cancer Research, University of Tennessee Health Science Center
Co-authored papers 7
Lewis C Cantley
Co-authored papers 6
Wilhelm Haas
Co-authored papers 6
Phuong Vu
Harvard Medical School
Co-authored papers 6
Peter S Hammerman
Novartis Institutes for BioMedical Research
Co-authored papers 5
Marcia C Haigis
Co-authored papers 5
Raul Mostoslavsky
Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School
Co-authored papers 5
Anthony J Iafrate
Massachusetts General Hospital
Co-authored papers 5
Jochen K Lennerz
Massachusetts General Hospital/Harvard Medical School
Co-authored papers 4
Orian S Shirihai
David Geffen School of Medicine (L.S., University of California los angeles
Co-authored papers 4
Yuval Dor
Hadassah-Hebrew University Medical Center
Co-authored papers 4
Massimo Loda
Weill Medical College of Cornell University
Co-authored papers 4
Daniela Sia
Co-authored papers 4
John D Gordan
Quantitative Biosciences Institute (QBI), University of California San Francisco
Co-authored papers 4
Pasi A J??nne
Dana-Farber Cancer Institute
Co-authored papers 4
Manisha Sinha
Co-authored papers 3
Patrice M Milos
Co-authored papers 3
John Alan Diehl
Case Western Reserve University School of Medicine
Co-authored papers 3
Qing Zhang
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Co-authored papers 3
Glenn Merlino
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 3
Todd R Golub
Broad Institute of MIT and Harvard
Co-authored papers 3
Samir M Hanash
University of Texas MD Anderson Cancer Center
Co-authored papers 3
David E Housman
Co-authored papers 3
Kun-Liang Guan
University of California San Diego
Co-authored papers 3
Marcus Bosenberg
Yale School of Medicine
Co-authored papers 3
Release 1.2